CN105452227B - {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形 - Google Patents

{[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形 Download PDF

Info

Publication number
CN105452227B
CN105452227B CN201480016402.9A CN201480016402A CN105452227B CN 105452227 B CN105452227 B CN 105452227B CN 201480016402 A CN201480016402 A CN 201480016402A CN 105452227 B CN105452227 B CN 105452227B
Authority
CN
China
Prior art keywords
compound
acetic acid
chlorophenoxy
isoquinoline
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480016402.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105452227A (zh
Inventor
克劳迪娅·维奇
迈克尔·D·汤普森
朴郑民
迈克尔·P·阿伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105452227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of CN105452227A publication Critical patent/CN105452227A/zh
Application granted granted Critical
Publication of CN105452227B publication Critical patent/CN105452227B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480016402.9A 2013-01-24 2014-01-23 {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形 Active CN105452227B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756361P 2013-01-24 2013-01-24
US61/756,361 2013-01-24
PCT/US2014/012780 WO2014116849A1 (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Publications (2)

Publication Number Publication Date
CN105452227A CN105452227A (zh) 2016-03-30
CN105452227B true CN105452227B (zh) 2018-05-29

Family

ID=50073508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480016402.9A Active CN105452227B (zh) 2013-01-24 2014-01-23 {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形

Country Status (15)

Country Link
US (1) US9643928B2 (enExample)
EP (1) EP2951159B1 (enExample)
JP (1) JP6437456B2 (enExample)
KR (1) KR102233081B1 (enExample)
CN (1) CN105452227B (enExample)
AU (1) AU2014209319B2 (enExample)
CA (1) CA2899024C (enExample)
DK (1) DK2951159T3 (enExample)
ES (1) ES2694297T3 (enExample)
IL (1) IL240066B (enExample)
MX (1) MX360048B (enExample)
RU (1) RU2666144C2 (enExample)
SG (2) SG11201505748UA (enExample)
TW (1) TWI685487B (enExample)
WO (1) WO2014116849A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001101A2 (pt) 2012-07-16 2017-06-27 Fibrogen Inc formas cristalinas de um inibidor de prolil hidroxilase
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
JP2023518392A (ja) * 2020-03-17 2023-05-01 ザイダス ライフサイエンシズ リミティド Ｈｉｆプロリルヒドロキシラーゼ阻害剤を含む製剤組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374815A (zh) * 2006-01-27 2009-02-25 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
WO2009075826A1 (en) * 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (de) 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DK0944619T3 (da) 1996-11-27 2007-02-05 Bristol Myers Squibb Pharma Co Hidtil ukendte integrinreceptorantagonister
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2003053997A2 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060173046A1 (en) 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
CN1832920A (zh) 2003-08-08 2006-09-13 特兰斯泰克制药公司 芳基和杂芳基化合物,组合物及其使用方法
JP2008507097A (ja) 2004-07-15 2008-03-06 パワープリサイス・ソリューションズ・インコーポレーテッド ワンタイム動作状態検出方法および装置
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
KR20080097446A (ko) * 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
KR101084635B1 (ko) 2006-04-04 2011-11-18 피브로겐, 인크. Ｈｉｆ 조절제로서 피롤로- 및 티아졸로-피리딘 화합물
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374815A (zh) * 2006-01-27 2009-02-25 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
WO2009075826A1 (en) * 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Crystalline Polymorphism of Organic Compounds;Mino R.Caira;《Topics in Current Chemistry》;19981231;第198卷;164-208 *

Also Published As

Publication number Publication date
EP2951159A1 (en) 2015-12-09
JP6437456B2 (ja) 2018-12-12
KR20150129679A (ko) 2015-11-20
TWI685487B (zh) 2020-02-21
SG10202009266PA (en) 2020-10-29
CN105452227A (zh) 2016-03-30
US20160002170A1 (en) 2016-01-07
RU2666144C2 (ru) 2018-09-06
ES2694297T3 (es) 2018-12-19
KR102233081B1 (ko) 2021-03-29
IL240066B (en) 2019-08-29
CA2899024C (en) 2022-01-04
IL240066A0 (en) 2015-09-24
MX2015009617A (es) 2016-04-20
CA2899024A1 (en) 2014-07-31
US9643928B2 (en) 2017-05-09
MX360048B (es) 2018-10-19
DK2951159T3 (en) 2018-11-19
AU2014209319B2 (en) 2018-04-19
HK1217331A1 (en) 2017-01-06
JP2016505071A (ja) 2016-02-18
EP2951159B1 (en) 2018-08-22
WO2014116849A1 (en) 2014-07-31
RU2015134420A (ru) 2017-03-03
SG11201505748UA (en) 2015-08-28
AU2014209319A1 (en) 2015-08-27
TW201444800A (zh) 2014-12-01

Similar Documents

Publication Publication Date Title
CN105452227B (zh) {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形
CN103539735B (zh) 脯氨酰羟化酶抑制剂的晶体形态
HK1217331B (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HK40003887A (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241367B (zh) 脯氨醯羥化酶抑制劑的晶體形態
HK1241365B (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241367A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241394A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
TW201518279A (zh) 脯胺醯羥化酶抑制劑的晶體形態

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant